Ionizable Lipid — ALC-0315 Type (Research Grade)
Research-grade ionizable lipid of the ALC-0315 type — the second-generation structure used in the Pfizer–BioNTech COVID-19 vaccine and the reference formulation for a large share of published LNP research. pH-responsive, ≥98% purity, −20 °C cold chain. Research use only.
Catalog no. IL-ALC-1G / IL-ALC-10G / IL-ALC-100G · Ships with certificate of analysis
For Research Use OnlyOverview
Overview
ALC-0315 is the second-generation ionizable lipid used in the Pfizer–BioNTech COVID-19 vaccine, and it remains the reference structure for a large share of published LNP research: when a paper or protocol calls for an ALC-0315 formulation, this is the material that answers.
This is a research-grade equivalent of that structure — not the original manufacturer's product — supplied strictly for research use. At acidic pH it is protonated and positively charged, complexing and encapsulating negatively charged nucleic acids; at physiological pH it returns to near-neutral, reducing toxicity; after uptake it promotes endosomal escape.
For commercial-track programmes free of foreign-patent exposure, see our proprietary ionizable lipid with China / US / EU patents and CDE + FDA DMF filings.
Key specifications
| Chemical name | ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) |
|---|---|
| CAS number | 2036272-55-4 |
| Molecular formula | C48H95NO5 |
| Molecular weight | 766.3 |
| Purity | ≥98% (HPLC; full specification per COA) |
| Charge behaviour | pH-responsive — protonated at low pH, near-neutral at physiological pH |
| Role | nucleic-acid complexation and encapsulation; endosomal escape |
| Form | waxy / oily (solid at low temperature — temper before use per protocol) |
| Storage | −20 ± 5 °C, dry and sealed, protected from light |
| Quality system | ISO 9001 / ISO 13485; manufactured under ICH-Q7A |
| Intended use | For Research Use Only |
Pack sizes
| Size | Part number |
|---|---|
| 1 g | IL-ALC-1G |
| 10 g | IL-ALC-10G |
| 100 g | IL-ALC-100G |
Larger pack sizes are quoted at enquiry.
Key features
- The named structure researchers ask for — direct search demand from every lab replicating or benchmarking against ALC-0315 formulations
- pH-responsive performance — tight nucleic-acid complexation at low pH, near-neutral at physiological pH, strong endosomal escape
- Domestic capacity, import-beating pricing — ten-kilogram-per-batch production at the source factory, from 1 g research packs to 100 g pilot quantities
- Complete quality system — ISO 9001 / 13485, ICH-Q7A production, consistent between batches
- Light-protective packaging — dark vials reduce lipid oxidation risk during storage
Applications
mRNA vaccine and therapeutic LNP research on ALC-0315-based formulations; siRNA and oligonucleotide delivery research; CRISPR and gene-editing delivery; method-reproduction and control experiments aligned to published ALC-0315 protocols; gram-to-hundred-gram supply with custom structures on request.
Notes
- Patented structure — research use only. The ALC-0315 structure remains under foreign patent until approximately 2036–2038. This material is supplied exclusively for research applications; it is not offered for commercial or GMP-scale supply. Commercial-track enquiries are assessed case by case.
- Supplied as an ALC-0315 type equivalent — not the original manufacturer's product. No therapeutic or diagnostic claims are made or permitted.
- Cold-chain product — stored at −20 °C and shipped on dry ice; export packaging and transport conditions confirmed at order.
- Catalogue codes, filing references, COA, MSDS, ISO certificates, FOB pricing, MOQ and lead time are provided one-to-one at enquiry.
| Product | Ionizable Lipid — ALC-0315 Type (Research Grade) |
|---|---|
| Catalog no. | IL-ALC-1G / IL-ALC-10G / IL-ALC-100G |
| Category | Lipids & Materials |
| Documentation | Certificate of analysis provided with every lot |
| Intended use | For Research Use Only (RUO). Not for diagnostic or therapeutic use. |
Related products
Ionizable Lipid — Proprietary Patented Structure
The core functional component of an LNP: a pH-responsive ionizable lipid with a proprietary, independently patented structure — not an SM-102 / ALC-0315 / MC3 analogue. China / US / EU patents; CDE excipient registration and FDA DMF filing completed. ISO 9001 / 13485, ICH-Q7A production.
Ionizable Lipid — MC3 Type (D-Lin-MC3-DMA, Research Grade)
Research-grade ionizable lipid of the MC3 (D-Lin-MC3-DMA) type — the first-generation benchmark lipid of Onpattro, the first approved siRNA drug. pKa ≈ 6.44, ≥98% purity, −20 °C cold chain. Research use only.
Vaccinia Capping Enzyme (mRNA 5' Capping, Cap 0/Cap 1)
Recombinant vaccinia capping enzyme (D1-D12) with three-in-one activity for enzymatic mRNA 5' capping — ~100% Cap 0 in 1 hour, upgradeable to Cap 1. Low endotoxin, low host residuals, RUO.
Get a quote for Ionizable Lipid — ALC-0315 Type (Research Grade)
Specs, pricing, lead time and shipping options — usually within one business day.